Patents by Inventor Konrad Noben-Trauth

Konrad Noben-Trauth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6114502
    Abstract: Nucleic acid compositions are provided that encode a family of mammalian proteins expressed in the retina and brain. Members of the gene family are genetically linked to various neurosensory defects, including cochlear degeneration, peripheral retinal degeneration and cone-rod retinal dystrophy. The nucleic acid compositions find use in identifying DNA sequences encoding homologous or related proteins; for production of the encoded protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of neurosensory defects, identification of retinal cells based on expression, and the like. The DNA is further used as a diagnostic for genetic predisposition to the linked neurosensory defect.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: September 5, 2000
    Assignee: AxyS Pharmaceuticals, Inc.
    Inventors: Michael North, Patsy Nishina, Juergen Naggert, Konrad Noben-Trauth
  • Patent number: 5776762
    Abstract: The gene responsible for the autosomal recessive mouse obesity mutation tub was identified by positional cloning. The homologous human gene is also provided. The genes are used to produce tubby protein; in screening for compositions that modulate the expression or function of the tubby protein; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to obesity, retinal degeneration or cochlear degeneration. The mutation responsible for the tub phenotype is a G to T transversion that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. A second, prematurely truncated transcript arises from the introduction of a premature polyadenylation site in the unspliced intron.
    Type: Grant
    Filed: September 17, 1996
    Date of Patent: July 7, 1998
    Assignees: Sequana Therapeutics, Inc., The Jackson Laboratory
    Inventors: Michael North, Patsy Nishina, Konrad Noben-Trauth, Juergen Naggert
  • Patent number: 5770432
    Abstract: The gene responsible for the autosomal recessive mouse obesity mutation tub was identified by positional cloning. The homologous human gene is also provided. The genes are used to produce tubby protein; in screening for compositions that modulate the expression or function of the tubby protein; and in studying associated physiological pathways. The DNA is further used as a diagnostic for genetic predisposition to obesity, retinal degeneration or cochlear degeneration. The mutation responsible for the tub phenotype is a G to T transversion that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. A second, prematurely truncated transcript arises from the introduction of a premature polyadenylation site in the unspliced intron.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: June 23, 1998
    Assignees: Sequana Therapeutics, Jackson Laboratory
    Inventors: Patsy Nishina, Konrad Noben-Trauth, Juergen Naggert, Michael North